StreetInsider.com News Articles

Form 4 AN2 Therapeutics, Inc. For: May 29 Filed by: Williams Sarah Joanne

Tue, 02 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260602/26592279.html

Form 4 AN2 Therapeutics, Inc. For: May 29 Filed by: Williams Sarah Joanne

Tue, 02 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260602/26592279.html

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

Thu, 21 May 2026 07:00:00 -0400

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 12:50 PM ET, and members of management will be available for 1x1 meetings.

A webcast can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.

About AN2 Therapeutics, Inc.

AN2 Therapeutics,

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

Thu, 21 May 2026 07:00:00 -0400

A webcast can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.

About AN2 Therapeutics, Inc.

AN2 Therapeutics,

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

Thu, 21 May 2026 07:00:00 -0400

A webcast can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.

About AN2 Therapeutics, Inc.

AN2 Therapeutics,

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

Thu, 21 May 2026 07:00:00 -0400

A webcast can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.

About AN2 Therapeutics, Inc.

AN2 Therapeutics,

Form SCHEDULE 13G/A AN2 Therapeutics, Inc. Filed by: Almitas Capital LLC

Fri, 15 May 2026 21:59:00 -0400

si-local-file:///var/storage/secattach/20260515/26508566.html

Form SCHEDULE 13G/A AN2 Therapeutics, Inc. Filed by: Almitas Capital LLC

Fri, 15 May 2026 21:59:00 -0400

si-local-file:///var/storage/secattach/20260515/26508566.html

Leerink Partners Upgrades AN2 Therapeutics (ANTX) to Outperform

Thu, 14 May 2026 06:08:27 -0400

Leerink Partners analyst Joseph Schwartz upgraded AN2 Therapeutics (NASDAQ: ANTX) from Market Perform to Outperform with a price target of $9.00.

For an analyst ratings summary and ratings history on AN2 Therapeutics click here. For more ratings news on AN2 Therapeutics click here.

Shares of AN2 Therapeutics closed at $4.31 yesterday.

AN2 Therapeutics, Inc. (ANTX) Misses Q1 EPS by 6c

Mon, 11 May 2026 17:04:59 -0400

AN2 Therapeutics, Inc. (NASDAQ: ANTX) reported Q1 EPS of ($0.29), $0.06 worse than the analyst estimate of ($0.23).

For earnings history and earnings-related data on AN2 Therapeutics, Inc. (ANTX) click here.

Form 10-Q AN2 Therapeutics, Inc. For: Mar 31

Mon, 11 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260511/26469062.html

Form 10-Q AN2 Therapeutics, Inc. For: Mar 31

Mon, 11 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260511/26469062.html

Form 8-K AN2 Therapeutics, Inc. For: May 11

Mon, 11 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260511/26468987.html

Form 8-K AN2 Therapeutics, Inc. For: May 11

Mon, 11 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260511/26468987.html

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

Mon, 11 May 2026 16:01:00 -0400

Oral epetraborole program in polycythemia vera advancing toward Phase 2

Phase 2 investigator-initiated trial with epetraborole for M. abscessus lung disease underway

Data expected in 2Q/2026 from two studies of oral AN2-502998, under development for chronic Chagas disease: a Phase 1 first-in-human clinical trial and a non-human primate efficacy study

Declared ENPP1 candidate for solid tumors advancing from early research into development

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

Mon, 11 May 2026 16:01:00 -0400

Oral epetraborole program in polycythemia vera advancing toward Phase 2

Phase 2 investigator-initiated trial with epetraborole for M. abscessus lung disease underway

Data expected in 2Q/2026 from two studies of oral AN2-502998, under development for chronic Chagas disease: a Phase 1 first-in-human clinical trial and a non-human primate efficacy study

Declared ENPP1 candidate for solid tumors advancing from early research into development

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

Mon, 11 May 2026 16:01:00 -0400

Oral epetraborole program in polycythemia vera advancing toward Phase 2

Phase 2 investigator-initiated trial with epetraborole for M. abscessus lung disease underway

Data expected in 2Q/2026 from two studies of oral AN2-502998, under development for chronic Chagas disease: a Phase 1 first-in-human clinical trial and a non-human primate efficacy study

Declared ENPP1 candidate for solid tumors advancing from early research into development

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

Mon, 11 May 2026 16:01:00 -0400

Oral epetraborole program in polycythemia vera advancing toward Phase 2

Phase 2 investigator-initiated trial with epetraborole for M. abscessus lung disease underway

Data expected in 2Q/2026 from two studies of oral AN2-502998, under development for chronic Chagas disease: a Phase 1 first-in-human clinical trial and a non-human primate efficacy study

Declared ENPP1 candidate for solid tumors advancing from early research into development

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Thu, 07 May 2026 16:01:00 -0400

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 19, 2026 at 4:00 PM ET, and members of management will be available for 1x1 meetings.

A webcast can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Thu, 07 May 2026 16:01:00 -0400

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 19, 2026 at 4:00 PM ET, and members of management will be available for 1x1 meetings.

A webcast can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Thu, 07 May 2026 16:01:00 -0400

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 19, 2026 at 4:00 PM ET, and members of management will be available for 1x1 meetings.

A webcast can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Thu, 07 May 2026 16:01:00 -0400

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 19, 2026 at 4:00 PM ET, and members of management will be available for 1x1 meetings.

A webcast can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the

Form ARS AN2 Therapeutics, Inc. For: Dec 31

Wed, 22 Apr 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260422/26351196.html

Form ARS AN2 Therapeutics, Inc. For: Dec 31

Wed, 22 Apr 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260422/26351196.html

Form DEF 14A AN2 Therapeutics, Inc. For: Apr 22

Wed, 22 Apr 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260422/26351168.html